XN omikronrekombinantti BA.1*/BA.2

 

XN

United Kingdom 99.0%, Denmark 1.0%

20220213.

76

93

Recombinant lineage of BA.1 and BA.2, UK lineage, from pango-designation issue #480

XN rekombinantti BA.1*/BA.2 merkattu 18 päivää sitten.

Potential BA.1*/BA.2 Recombinant with Likely Breakpoint at NSP3 (104 Seqs in UK-England as of 2022-03-29) #480

“Description

Recombinant between: BA.1* & BA.2
Earliest sequence: 2022/2/1 (UK-England)
Most recent sequence: 2022/3/15 (UK-England)
Countries circulating: UK
Likely breakpoint: between 2834 and 4183 at NSP3.
Conserved Nuc mutations (those in red frames are likely from the donor from the BA.1* side):

Cov-spectrum query: A2832G, G4184A, G10986A, A29510C
GISAID query: NSP3_K38R, N_S413R, NSP6_R5K, NSP3_G489S”

“There are 104 sequences as of 2022-03-29, of which one is detected in Canada-Ontario”.

“And according to Cov-spectrum, there's a growth advantage over BA.2 in UK since 2022-02-01”.

(Sitaatteja tiedemiesten keskustelusta:)

“It makes me wonder if BA.1-BA.2 recombinants like this one (and also XE, which has a similar breakpoint) might really have some fitness advantage over both BA.1 and BA.2.”

18 päivää sitten on merkintä XN rekombinantin siirtämisestä varmistamisesta uudeksi linjakseen.

Sitaatti:

“Added new lineage XN from #480 with 76 new sequence designations”

Muistiin 19.4. 2022